Revelation Biosciences, Inc. (NASDAQ:REVB) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Headlines Articles Press releases Revelation Biosciences, Inc.

Home
Companies
Revelation Biosciences, Inc.

BRIEF

published on 09/11/2025 at 14:35, 2 months 23 days ago

Revelation Biosciences Inc. Raises $9.6 Million Through Warrant Exercise

Nasdaq Listing Clinical-stage Warrant Exercise Revelation Biosciences Inflammation Rebalancing
PRESS RELEASE

published on 09/11/2025 at 14:30, 2 months 23 days ago

Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds
Revelation Biosciences, Inc. announces immediate exercise of warrants for purchase of common stock. Private placement agreement with new Class I warrants. Roth Capital Partners as financial advisor

Private Placement Common Stock Warrants Exercise Roth Capital Partners Revelation Biosciences
BRIEF

published on 09/10/2025 at 13:25, 2 months 24 days ago

Revelation Biosciences Reports Positive Clinical Data for Gemini

Chronic Kidney Disease Clinical Study Results Gemini Revelation Biosciences Inflammation Treatment
PRESS RELEASE

published on 09/10/2025 at 13:20, 2 months 24 days ago

Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data
Gemini showed significant reduction in inflammation at the cellular level in CKD patients according to Phase 1b study results. Groundbreaking potential in inflammatory disease treatment

Inflammation CKD Gemini Phase 1b Study Cellular Level
BRIEF

published on 09/09/2025 at 23:00, 2 months 25 days ago

Revelation Biosciences Set to Discuss Phase 1b Data in Upcoming Conference Call

Clinical Trials Webcast Inflammation Revelation Biosciences Phase 1b Study
PRESS RELEASE

published on 09/09/2025 at 22:55, 2 months 25 days ago

Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
Revelation Biosciences, Inc. (NASDAQ:REVB) reminds of webcast on Sept 10, 8:30 am ET. Focus on inflammation. Seeking to rebalance inflammation for various medical conditions

Webcast Clinical-stage Inflammation Gemini Revelation Biosciences
BRIEF

published on 09/09/2025 at 14:05, 2 months 25 days ago

Revelation Biosciences' PRIME Study Shows Promising Results for Gemini in Inflammatory Diseases

Clinical Results Gemini Revelation Biosciences PRIME Study Inflammation Treatment
PRESS RELEASE

published on 09/09/2025 at 14:00, 2 months 25 days ago

Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study
Revelation Biosciences reports positive safety and activity data for Gemini in phase 1b PRIME study for CKD patients, showing reduction in inflammatory activity and cellular response normalization

Clinical Study Gemini Revelation Biosciences CKD Patients Inflammatory Response

Accesswire

Published on 12/05/2025 at 02:35, 4 hours 36 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 4 hours 41 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 6 hours 11 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 6 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 11 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 07:00, 10 minutes ago

Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 40 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 20 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 45 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 56 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025

Les Echos

Published on 12/04/2025 at 18:00, 13 hours 11 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 26 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 26 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE